Market Opportunity
Global Market for Refractory Epilepsy
- Globally: 17.5M refractory epilepsy patients
- US & Canada: ~70,000 patients
- $2.8B+ serviceable addressable market
- Safer alternative to Epidiolex
- Cannabinoid platform for new indications
- Best-in-class advantage in rare syndromes
Market Opportunity
A $1.9B+ Global Market in Epilepsy Alone
High Impact Entry into a $1.9 B+ Epilepsy Market Alone
- 50 million patients globally suffer from epilepsy
- 30% 40% (~17.5M) have refractory epilepsy underserved & drug resistant
- $1.9B global market, expanding with high unmet need
Expansion Potential Across Neurological Conditions
- CQ 001 shows 35% higher efficacy vs. CBD alone applicable to anxiety, PTSD, depression, and more
- Fewer side effects: Reduced liver toxicity, cognitive decline, fatigue, insomnia, mood swings
Breakthrough Platform Advantage
- Powered by The Synergistic Effect: cannabi d iol + proprietary formulation
- Platform extends beyond epilepsy into mental health & neurological disorders
- Strong IP position & scalability for multi indication applications